Melola Discovery

← Melola Discovery

Journal

Interaction Study of BCN OH ( Bicyclononyn ) and Pertuzumab in the Development of ADC ( Antibody Drug Conjugation ) Through Virtual Screening

Indonesian Journal of Chemical Science · Vol. 13 No. 2 (2024) · pp. 143–150

ISSN
2502-6844, 2252-6951
Published
2024-08-23
Publisher
Prodi Kimia
Language
eng

Abstract

ADC (Antibody Drug Conjugation) is a complex molecule consisting of antibodies designed as a targeted therapy to treat disease, or a biologically active cytotoxic drug. Docking simulations of the pertuzumab antibody with the BCN OH ligand were carried out to see the interactions and stable conjugates between the antibody and the ligand as a form of ADC development using three software, consisting of Discovery Studio, pymol and pyrex. The pymol application is used for the preparation of pertuzumab, namely removing residues and water and is used to combine the ligand with the antibody, while the use of Pyrex Autodocx Vina is to determine the conformation of the ligand in binding with the macromolecule. Discovery studio is used to realize the bond between the linker and antibody and see the interactions that occur. This research aims to determine the interaction of pertuzumab with BCN OH as a starting point for selecting a suitable ligand for the ADC product so that later the ADC will be more stable until the target of the simulations carried out is obtained by the results of interactions that occur between pertuzumab and the BCN OH molecule. After being realized in two dimensions, it can be seen that there are amino acid compounds that bind to BCN OH on side B:103, there is lysine, side B:40 proline, side B:38 Arginine, side B:85 Threonine, and on side B:415 there is Air molecules. In the docking process, the presence of lysine bonds is an important factor in looking at the interaction of compounds with their macromolecules, considering that lysine is one of the residues that will bind to the functional groups on the linker to produce ADC products.

Collaboration network of the authors

16 authors · 66 co-authorship links

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Lintang Tri AnandaAffiliation unknown1
Aden Dhana RizkitaAffiliation unknown1
Syahrul Syah GibranAffiliation unknown1
Shari Bella ShapiraAffiliation unknown1
Shelly Siti Nour baetyAffiliation unknown1
Shahibatul WafaAffiliation unknown1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OAI-PMH (metadata jurnal) https://journal.unnes.ac.id/journals/ijcs/oai, first harvested 5 Nov 2026, last seen 8 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Interaction Study of BCN OH ( Bicyclononyn ) and Pertuzumab in the Development of ADC ( Antibody Drug Conjugation ) Through Virtual Screening</dc:title>
	<dc:creator xml:lang="en">Alwia, Nisa</dc:creator>
	<dc:creator xml:lang="en">Aden Dhana Rizkita1</dc:creator>
	<dc:creator xml:lang="en">Tris Ella Julita Gulo</dc:creator>
	<dc:creator xml:lang="en">Nisa Sri Wahyuni</dc:creator>
	<dc:creator xml:lang="en">Risma Eka Putri Selay</dc:creator>
	<dc:creator xml:lang="en">Ayu Andini Rizki Lestari Rohman</dc:creator>
	<dc:creator xml:lang="en">Efriyana Oksal</dc:creator>
	<dc:creator xml:lang="en">Kumam Pinky Chanu</dc:creator>
	<dc:creator xml:lang="en">Asaduzzaman</dc:creator>
	<dc:creator xml:lang="en">Taufik Muhammad Faqih5</dc:creator>
	<dc:description xml:lang="en">ADC (Antibody Drug Conjugation) is a complex molecule consisting of antibodies designed as a targeted therapy to treat disease, or a biologically active cytotoxic drug. Docking simulations of the pertuzumab antibody with the BCN OH ligand were carried out to see the interactions and stable conjugates between the antibody and the ligand as a form of ADC development using three software, consisting of Discovery Studio, pymol and pyrex. The pymol application is used for the preparation of pertuzumab, namely removing residues and water and is used to combine the ligand with the antibody, while the use of Pyrex Autodocx Vina is to determine the conformation of the ligand in binding with the macromolecule. Discovery studio is used to realize the bond between the linker and antibody and see the interactions that occur. This research aims to determine the interaction of pertuzumab with BCN OH as a starting point for selecting a suitable ligand for the ADC product so that later the ADC will be more stable until the target of the simulations carried out is obtained by the results of interactions that occur between pertuzumab and the BCN OH molecule. After being realized in two dimensions, it can be seen that there are amino acid compounds that bind to BCN OH on side B:103, there is lysine, side B:40 proline, side B:38 Arginine, side B:85 Threonine, and on side B:415 there is Air molecules. In the docking process, the presence of lysine bonds is an important factor in looking at the interaction of compounds with their macromolecules, considering that lysine is one of the residues that will bind to the functional groups on the linker to produce ADC products.</dc:description>
	<dc:publisher xml:lang="en">Prodi Kimia</dc:publisher>
	<dc:date>2024-08-23</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.unnes.ac.id/journals/ijcs/article/view/906</dc:identifier>
	<dc:source xml:lang="en">Indonesian Journal of Chemical Science; Vol. 13 No. 2 (2024): Indonesian Journal of Chemical Science; 143-150</dc:source>
	<dc:source>2502-6844</dc:source>
	<dc:source>2252-6951</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://journal.unnes.ac.id/journals/ijcs/article/view/906/1282</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2024 Indonesian Journal of Chemical Science</dc:rights>
</oai_dc:dc>